Vaxart Inc (VXRT)

$ 7.2
0.27 (+3.90%)
Neutral
Symbol VXRT
Price $ 7.2
Beta 0.101
Volume Avg. 17.81M
Market Cap 0.85B
Shares () -
52 Week Range 2.23-24.9
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -28.05% Sell
ROA -16.06% Sell
Operating Margin -
Debt / Equity 16.81% Neutral
P/E -
P/B 4.40 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Better Vaccine Stock: Ocugen or Vaxart?

Better Vaccine Stock: Ocugen or Vaxart?

Here's how the biotechs compare on several key fronts. ...

The Motley Fool
Vaxart's Vaccine Candidate Is a Pill, Not a Shot. Does It Matter?

Vaxart's Vaccine Candidate Is a Pill, Not a Shot. Does It Matter?

If it can reach the market of people that are hesitant to be vaccinated, yes. ...

The Motley Fool
Why Vaxart Stock Is Surging Today

Why Vaxart Stock Is Surging Today

Investors are excited about the company's experimental COVID-19 vaccine. ...

The Motley Fool
Vaxart Stock Surges on Oral Covid-19 Vaccine Update

Vaxart Stock Surges on Oral Covid-19 Vaccine Update

The shares of biotechnology concern Vaxart Inc (NASDAQ:VXRT) are up a whopping 11.5% to trade at $8.94 at last check , after the company announced its oral coronavirus vaccine produced positive phase 1 trial results. ...

Schaeffers Research
Why Vaxart Shares Popped 78% in April

Why Vaxart Shares Popped 78% in April

Shareholders keep getting their hopes up for the company's tablet-based COVID-19 vaccine. ...

The Motley Fool
Vaxart Stock Is Surging As Its Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Variants

Vaxart Stock Is Surging As Its Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Varian...

Vaxart Inc (NASDAQ: VXRT) has announced new data from the Phase 1 trial evaluating its oral COVID-19 vaccine candidate, dubbed as VXA-CoV2-1. Data obtained showed substantial CD8+ T-cell responses against SARS-Cov-2 and showed cross-reactivity agains... ...

Benzinga
VXRT Stock: From $8.02 To $9.48 (18.2% Increase) Pre-Market Explanation

VXRT Stock: From $8.02 To $9.48 (18.2% Increase) Pre-Market Explanation

The stock price of Vaxart Inc (NASDAQ: VXRT) increased from $8.02 to $9.48 (up 18.2%) pre-market. This is why it happened. ...

Pulse2
New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses

New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Oth...

Vaxart oral vaccine induced higher CD8 + T-Cell responses than those seen with  Moderna or Pfizer vaccines in comparative experiment conducted by the Company ...

GlobeNewsWire
VAXART, INC. (VXRT) Reports Q1 Loss, Misses Revenue Estimates

VAXART, INC. (VXRT) Reports Q1 Loss, Misses Revenue Estimates

VAXART, INC. (VXRT) delivered earnings and revenue surprises of -40.00% and -17.99%, respectively, for the quarter ended March 2021. ...

Zacks Investment Research
VXRT Stock: From $10.78 To Over $12.15 Pre-Market

VXRT Stock: From $10.78 To Over $12.15 Pre-Market

The stock price of Vaxart Inc (NASDAQ: VXRT) increased from $10.78 to over $12.15 during pre-market trading as of 4:07 AM ET today. This is why it happened. ...

Pulse2

About


Dr. Wouter Latour
Healthcare
Biotechnology
Nasdaq Capital Market

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. The company is headquartered in South San Francisco, California and currently employs 28 full-time employees. The firm has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. The company has preclinical RSV non-fusion inhibitor program. The company has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.